Monitoring minimal residual disease in multiple myeloma by mass spectrometry
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial is for multiple myeloma patients who have achieved a stringent complete remission (sCR) for at least six months. It uses a blood test to look for very small traces of myeloma cells, which may help monitor treatment success.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have multiple myeloma and have been in stringent complete remission for more than 6 months.
- You had a diagnostic bone marrow and blood sample stored in a biobank at diagnosis.
- You are able to understand and read Danish.
- You do not have a bleeding disorder or very low platelet counts (under 20 billion per liter).
- You give written consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with newly diagnosed multiple myeloma whose cancer responded to initial treatment but still has tiny traces (minimal residual disease, or MRD). The trial will test if adjusting the next phase of therapy based on MRD levels can improve long-term outcomes.
This study tests a genetic technology (ClonoSeq-based) to detect very small amounts of multiple myeloma that may remain after treatment. It may help doctors better track how well treatment is working and predict how the disease responds over time.
This study looks at whether small leftover signs of multiple myeloma in blood or bone marrow (called measurable residual disease, or MRD) can predict how well treatment works. It involves people already taking study treatment in a larger trial and checks results about two years later to see who benefits most.
This study looks at stored blood (serum) samples to see whether a lab test called MALDI-TOF mass spectrometry can help analyze multiple myeloma proteins. If you have multiple myeloma (or are a healthy matched control), your existing lab samples may be used for testing.
This trial tests a treatment plan for people with newly diagnosed high-risk multiple myeloma. It uses a special test called minimal residual disease (MRD) detection to see how well the treatment is working and guide next steps.
This study looks at whether people with newly diagnosed multiple myeloma can safely continue or adjust treatment after they reach “MRD-negative,” meaning very low signs of disease in the bone marrow. It may help reduce the chance of relapse while avoiding unnecessary treatment for some patients.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.